Cellectis (NASDAQ:CLLS) Issues Earnings Results

Cellectis (NASDAQ:CLLS) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03), Zacks reports. Cellectis had a negative return on equity of 78.90% and a negative net margin of 401.83%. The company had revenue of $18.05 million for the quarter, compared to analysts’ expectations of $5.00 million. During the same quarter in the prior year, the firm posted ($0.31) EPS.

Cellectis Stock Performance

CLLS stock traded up $0.05 during trading on Tuesday, hitting $1.81. The company had a trading volume of 40,776 shares, compared to its average volume of 47,794. The firm has a market cap of $100.60 million, a PE ratio of -1.36 and a beta of 3.10. The company has a quick ratio of 1.92, a current ratio of 1.92 and a debt-to-equity ratio of 0.39. The firm has a 50-day moving average price of $2.09 and a 200-day moving average price of $2.28. Cellectis has a 1-year low of $1.75 and a 1-year high of $3.77.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on CLLS shares. StockNews.com started coverage on Cellectis in a research report on Tuesday. They set a “sell” rating on the stock. Barclays reduced their price objective on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research note on Tuesday.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.